Marked Loss of Muscle, Visceral Fat, or Subcutaneous Fat After Gastrectomy Predicts Poor Survival in Advanced Gastric Cancer: Single-Center Study from the CLASSIC Trial-Reference-Cited by-同舟云学术

Marked Loss of Muscle, Visceral Fat, or Subcutaneous Fat After Gastrectomy Predicts Poor Survival in Advanced Gastric Cancer: Single-Center Study from the CLASSIC Trial

Published:2018-07-26 Issue:11 Volume:25 Page:3222-3230
ISSN:1068-9265
Container-title:Annals of Surgical Oncology
language:en
Short-container-title:Ann Surg Oncol

Author:

Park Hyung Soon,Kim Hyo Song,Beom Seung Hoon,Rha Sun Young,Chung Hyun Cheol,Kim Jee Hung,Chun You Jin,Lee Si Won,Choe Eun-Ah,Heo Su Jin,Noh Sung Hoon,Hyung Woo Jin,Cheong Jae-Ho,Kim Hyoung-Il,Son Taeil,Lim Joon Seok,Baek Song-Ee,Jung Minkyu

Funder

2014 faculty research grant from the Yonsei University College of Medicine

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Surgery

Link

http://link.springer.com/article/10.1245/s10434-018-6624-1/fulltext.html

Reference28 articles.

1. Jung KW, Won YJ, Oh CM, Kong HJ, Lee DH, Lee KH. Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2014. Cancer Res Treat. 2017;49:292–305.

2. Digklia A, Wagner AD. Advanced gastric cancer: Current treatment landscape and future perspectives. World J Gastroenterol. 2016;22:2403–14.

3. Noh SH, Park SR, Yang HK, et al. Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial. Lancet Oncol. 2014;15:1389–96.